Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress

Michelle T. Lee; Dhruv Mahtta; Louis Dlouhy; Hunaina Shahab; Mahmoud Al Rifai; Salim S. Virani

doi:10.1007/s11883-021-00975-8

Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress

Michelle T. Lee, Dhruv Mahtta, Louis Dlouhy, Hunaina Shahab, Mahmoud Al Rifai, Salim S. Virani

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Purpose of Review: This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress. Recent Findings: Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE). Summary: Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.

Original language	English (US)
Article number	76
Journal	Current Atherosclerosis Reports
Volume	23
Issue number	12
DOIs	https://doi.org/10.1007/s11883-021-00975-8
State	Published - Dec 2021

Keywords

Aspirin
Atherosclerotic cardiovascular disease
Cardiovascular prevention
Dapagliflozin
Empagliflozin
Heart failure

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s11883-021-00975-8

Cite this

@article{14650a99ed5e4aa18aba77ae5ebbcfc5,

title = "Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress",

abstract = "Purpose of Review: This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress. Recent Findings: Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE). Summary: Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.",

keywords = "Aspirin, Atherosclerotic cardiovascular disease, Cardiovascular prevention, Dapagliflozin, Empagliflozin, Heart failure",

author = "Lee, {Michelle T.} and Dhruv Mahtta and Louis Dlouhy and Hunaina Shahab and {Al Rifai}, Mahmoud and Virani, {Salim S.}",

note = "Publisher Copyright: {\textcopyright} 2021, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.",

year = "2021",

month = dec,

doi = "10.1007/s11883-021-00975-8",

language = "English (US)",

volume = "23",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Current Medicine Group",

number = "12",

}

TY - JOUR

T1 - Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress

AU - Lee, Michelle T.

AU - Mahtta, Dhruv

AU - Dlouhy, Louis

AU - Shahab, Hunaina

AU - Al Rifai, Mahmoud

AU - Virani, Salim S.

PY - 2021/12

Y1 - 2021/12

N2 - Purpose of Review: This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress. Recent Findings: Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE). Summary: Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.

AB - Purpose of Review: This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress. Recent Findings: Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE). Summary: Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.

KW - Aspirin

KW - Atherosclerotic cardiovascular disease

KW - Cardiovascular prevention

KW - Dapagliflozin

KW - Empagliflozin

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=85117327191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117327191&partnerID=8YFLogxK

U2 - 10.1007/s11883-021-00975-8

DO - 10.1007/s11883-021-00975-8

M3 - Review article

C2 - 34648072

AN - SCOPUS:85117327191

SN - 1523-3804

VL - 23

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 12

M1 - 76

ER -

Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this